APNmAb005 vs Etalanetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
APNmAb005
Developed by APRINOIA Therapeutics
NCT05344989 · Phase 1 · status unknown
This is a randomized, placebo-controlled study with full blinding of participants, care providers, and assessors, though it is an early, safety-focused, first-in-human study in healthy volunteers rather than a disease-population efficacy trial, with small dose-cohort sizes. Results have not yet been posted.
No aligned efficacy figure on record for this race.
Etalanetug
Developed by Eisai
NCT04971733 · Phase 1/2 · completed
The study treated 8 participants with etalanetug (E2814, Eisai's development code for this antibody) in open-label, single-arm cohorts without randomization, blinding or a comparator. Its primary endpoint was safety (treatment-emergent adverse events), not a controlled efficacy comparison, so it is weak evidence of efficacy.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
Reported efficacy
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug up to 120 weeks); Number of Participants With Markedly Abnormal Laboratory Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Vital Signs Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings (From first dose of study drug up to 120 weeks); Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 Weeks (Pre-dose at Week 12): Safety: three participants had treatment-related adverse events at the 3000 mg dose, and 5 serious adverse events occurred in 3 participants. Target engagement: CSF MTBR-tau243 fell 50.6% after 12 weeks (n=7), with a maximum reduction of 71.6% at week 36 (n=4); CSF ptau217 fell 30.4% at 12 weeks (n=7). Eight participants enrolled; no control group. (not_applicable)
Result source: NCT04971733
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | APNmAb005 | Etalanetug |
|---|---|---|
| CDR-SB, change | —Not reported | —Trial running · NCT01760005 |
| ADAS-Cog11, change | —Not reported | —Trial running · NCT01760005 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT01760005 |
| MMSE, change | —Not reported | —Trial running · NCT01760005 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT01760005 |
CDR-SB, change
- APNmAb005
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
ADAS-Cog11, change
- APNmAb005
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
ADCS-ADL, change
- APNmAb005
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
MMSE, change
- APNmAb005
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
Amyloid PET, change (centiloids)
- APNmAb005
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
APNmAb005: no structured comparison results are available for Alzheimer's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. APNmAb005: 0 of 4 rows · Etalanetug: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Etalanetug |
|---|---|
| Dropout rate | —4500 mga NCT04971733 · Phase 1/2 |
| Discontinued due to AEs | —4500 mga NCT04971733 · Phase 1/2 |
| Serious AEs | 25%4500 mga NCT04971733 · Phase 1/2 |
| Most frequent reported AEs | show 2 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APNmAb005's landscape · Etalanetug's landscape